YUSUKE GOTO

Dr. YUSUKE GOTO

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RYRyutaro Yasudome
Ryutaro Yasudome
NSNaohiko Seki
Naohiko Seki
SAShunichi Asai
Shunichi Asai
YGYUSUKE GOTO
YUSUKE GOTO
YKYoshiaki Kita
Yoshiaki Kita
TOTakao Ohtsuka
Takao Ohtsuka
We recently determined the RNA sequencing-based microRNA (miRNA) expression signature of colorectal cancer (CRC). Analysis of the signature showed that the expression of both strands of pre-miR-139 (miR-139-5p, the guide strand, and miR-139-3p, the passenger strand) was significantly reduced in CRC tissues. Transient transfection assays revealed that expression of miR-139-3p blocked cancer cell malignant transformation (e.g., cell proliferation, migration, and invasion). Notably, expression of miR-139-3p markedly blocked RAC-alpha serine/threonine-protein kinase (AKT) phosphorylation in CRC cells. A combination of in silico database and gene expression analyses of miR-139-3p-transfected cells revealed 29 putative targets regulated by miR-139-3p in CRC cells. RNA immunoprecipitation analysis using an Argonaute2 (AGO2) antibody revealed that KRT80 was efficiently incorporated into the RNA-induced silencing complex. Aberrant expression of Keratin 80 (KRT80) was detected in CRC clinical specimens by immunostaining. A knockdown assay using small interfering RNA (siRNA) targeting KRT80 showed that reducing KRT80 expression suppressed the malignant transformation (cancer cell migration and invasion) of CRC cells. Importantly, inhibiting KRT80 expression reduced AKT phosphorylation in CRC cells. Moreover, hexokinase-2 (HK2) expression was reduced in cells transfected with the KRT80 siRNAs or miR-139-3p. The involvement of miRNA passenger strands (e.g., miR-139-3p) in CRC cells is a new concept in miRNA studies. Our tumor-suppressive miRNA-based approach helps elucidate the molecular pathogenesis of CRC.

9 January 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MMMasafumi Maruo
Masafumi Maruo
YGYUSUKE GOTO
YUSUKE GOTO
KMKanetaka Miyazaki
Kanetaka Miyazaki
AIAtsushi Inoue
Atsushi Inoue
KKKoichiro Kurokawa
Koichiro Kurokawa
TITomohiko Ichikawa
Tomohiko Ichikawa
Although novel techniques for avoiding incontinence during robot-assisted radical prostatectomy have been developed, long-term oncological outcomes are unknown. The objective of this study was to determine the long-term oncological outcomes and functional outcomes of novel nerve-sparing robot-assisted radical prostatectomy with endopelvic fascia preservation for a single surgeon. Data from 100 patients who underwent structure-preserving prostatectomies performed by a single surgeon were retrospectively analyzed. The median console time was 123 min. Bilateral nerve-sparing was performed in 43% of patients underwent, and 57% underwent unilateral nerve-sparing surgery. Most patients (96%) reached complete pad-zero urinary continence by one year after surgery. Satisfactory erectile function was achieved in 97% of patients who underwent bilateral nerve-sparing surgery, and 80% of patients who underwent unilateral nerve-sparing surgery. The surgical margin was positive for 25% of patients, and the biochemical recurrence-free rate at 5 years was 77%. The cancer-specific survival rate was 100% during the median follow-up period of 4.5 years. Clavien-Dindo grade III complications occurred in 1% of cases. The outcomes for novel nerve-sparing robot-assisted radical prostatectomy with endopelvic fascia preservation were similar to previously reported oncological outcomes, with satisfactory functional outcomes. This operative method may be useful for patients who are eligible for nerve-sparing surgery.

1 July 2024 in Cancer Research Communications
Verified
Journal Article
Open access
YGYUSUKE GOTO
YUSUKE GOTO
KKKeiichi Koshizuka
Keiichi Koshizuka
TAToshinori Ando
Toshinori Ando
HIHiroki Izumi
Hiroki Izumi
XWXingyu Wu
Xingyu Wu
JGJ.Silvio Gutkind
J.Silvio Gutkind
The comprehensive genomic analysis of the head and neck squamous cell carcinoma (HNSCC) oncogenome revealed the frequent loss of p16INK4A (CDKN2A) and amplification of cyclin D1 genes in most human papillomavirus–negative HNSCC lesions. However, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have shown modest effects in the clinic. The aberrant activation of the PI3K/mTOR pathway is highly prevalent in HNSCC, and recent clinical trials have shown promising clinical efficacy of mTOR inhibitors (mTORi) in the neoadjuvant and adjuvant settings but not in patients with advanced HNSCC. By implementing a kinome-wide CRISPR/Cas9 screen, we identified cell-cycle inhibition as a synthetic lethal target for mTORis. A combination of mTORi and palbociclib, a CDK4/6-specific inhibitor, showed strong synergism in HNSCC-derived cells in vitro and in vivo. Remarkably, we found that an adaptive increase in cyclin E1 (CCNE1) expression upon palbociclib treatment underlies the rapid acquired resistance to this CDK4/6 inhibitor. Mechanistically, mTORi inhibits the formation of eIF4G–CCNE1 mRNA complexes, with the consequent reduction in mRNA translation and CCNE1 protein expression. Our findings suggest that mTORi reverts the adaptive resistance to palbociclib. This provides a multimodal therapeutic option for HNSCC by cotargeting mTOR and CDK4/6, which in turn may halt the emergence of palbociclib resistance. Significance: A kinome-wide CRISPR/Cas9 screen identified cell-cycle inhibition as a synthetic lethal target of mTORis. A combination of mTORi and palbociclib, a CDK4/6-specific inhibitor, showed strong synergistic effects in HNSCC. Mechanistically, mTORis inhibited palbociclib-induced increase in CCNE1.

5 February 2002 in The Journal of Agricultural Science
Verified
Journal Article
Closed access
PDF file
MTM. Tamaki
M. Tamaki
Satoru KondoSatoru Kondo
Satoru Kondo
TIT. Itani
T. Itani
YGYUSUKE GOTO
YUSUKE GOTO
Experiments were conducted in controlled environmental chambers to study the effects of temperature on leaf emergence and leaf growth of main stem in winter barley (Hordeum vulgare L.) plants. Plants of the cultivar, Kikai Hadaka, were grown at constant temperatures between 12·5 to 27·5 °C. The leaf number on the main stems was counted (in Haun units) every day from the emergence of the third leaf until the emergence of the seventh leaf. The area was measured from the second to the sixth leaves on the main stems. The emergence of new leaves was a linear function of time at all temperature regimes. The leaf emergence rate increased with increasing temperature until an optimum temperature of 22·5 °C was reached and then decreased with further increasing temperature, but not significantly, compared with the peak. The leaf emergence rate per degree-day (DD) was slower with increasing temperature. The leaf growth rate increased with increasing temperature until an optimum temperature of 20·0 °C was reached and then declined with further increases in temperature. The leaf growth rate per DD had its maximum at 17·5 °C. The leaf emergence and leaf growth under different temperatures but at the same DD were different. The responses to temperatures for emergence and growth of barley leaves were different. These results suggest that a fully developed concept of the relationship of temperature to plant development and growth is an important aspect of increasing the accuracy of dynamic crop simulation models.

24 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YHYoko Hagihara
Yoko Hagihara
YTYuya Tomioka
Yuya Tomioka
TSTakayuki Suetsugu
Takayuki Suetsugu
MSMasahiro Shinmura
Masahiro Shinmura
SMShunsuke Misono
Shunsuke Misono
NSNaohiko Seki
Naohiko Seki
Analyses of our microRNA (miRNA) expression signature combined with The Cancer Genome Atlas (TCGA) data revealed that both strands of pre-miR-139 (miR-139-5p, the guide strand, and miR-139-3p, the passenger strand) are significantly downregulated in lung adenocarcinoma (LUAD) clinical specimens. Functional analyses of LUAD cells ectopically expressing miR-139-3p showed significant suppression of their aggressiveness (e.g., cancer cell proliferation, migration, and invasion). The involvement of the passenger strand, miR-139-3p, in LUAD pathogenesis, is an interesting finding contributing to the elucidation of unknown molecular networks in LUAD. Of 1108 genes identified as miR-139-3p targets in LUAD cells, 21 were significantly upregulated in LUAD tissues according to TCGA analysis, and their high expression negatively affected the prognosis of LUAD patients. We focused on thyroid hormone receptor interactor 13 (TRIP13) and investigated its cancer-promoting functions in LUAD cells. Luciferase assays showed that miR-139-3p directly regulated TRIP13. siRNA-mediated TRIP13 knockdown and TRIP13 inhibition by a specific inhibitor (DCZ0415) attenuated the malignant transformation of LUAD cells. Interestingly, when used in combination with anticancer drugs (cisplatin and carboplatin), DCZ0415 exerted synergistic effects on cell proliferation suppression. Identifying the molecular pathways regulated by tumor-suppressive miRNAs (including passenger strands) may aid in the discovery of diagnostic markers and therapeutic targets for LUAD.

20 February 2023 in FEBS Letters
Verified
Journal Article
Closed access
SAShunichi Asai
Shunichi Asai
YGYUSUKE GOTO
YUSUKE GOTO
KTKengo Tanigawa
Kengo Tanigawa
YTYuya Tomioka
Yuya Tomioka
MKMayuko Kato
Mayuko Kato
NSNaohiko Seki
Naohiko Seki